Hybio Pharmaceutical Co., Ltd.
300199
Rangering i aksjer
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Aksjekurs
$3.69
Markedsverdi
$3.11B
Endring (1 dag)
-7.75%
Endring (1 år)
21.56%
Land
CN
Handel Hybio Pharmaceutical Co., Ltd. (300199)
Kategori
Healthcare
Driftsmargin for Hybio Pharmaceutical Co., Ltd. (300199)
Driftsmargin per October 2026 TTM: 17.45%
Ifølge Hybio Pharmaceutical Co., Ltd. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 17.45%. Ved slutten av 2024 hadde selskapet en driftsmargin på -27.34%.
Historikk for driftsmargin for Hybio Pharmaceutical Co., Ltd. fra 2007 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 17.45% | 144.06% |
| 2025 | 7.15% | -126.15% |
| 2024 | -27.34% | -76.76% |
| 2023 | -117.65% | 123.46% |
| 2022 | -52.65% | -1,091.53% |
| 2021 | 5.31% | -106.67% |
| 2020 | -79.58% | -46.01% |
| 2019 | -147.40% | 481.92% |
| 2018 | -25.33% | -189.06% |
| 2017 | 28.44% | -12.49% |
| 2016 | 32.50% | -24.10% |
| 2015 | 42.82% | -2.04% |
| 2014 | 43.71% | -7.37% |
| 2013 | 47.19% | 27.47% |
| 2012 | 37.02% | -5.54% |
| 2011 | 39.19% | -8.24% |
| 2010 | 42.71% | -0.58% |
| 2009 | 42.96% | 32.92% |
| 2008 | 32.32% | 5.00% |
| 2007 | 30.78% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 19.41% | -98.89% |
DE
|
|
| 19.68% | -98.87% |
DE
|
|
| 10.52% | -99.40% |
JP
|
|
| 17.08% | -99.02% |
CH
|
|
| 22.93% | -98.69% |
IN
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.